Literature DB >> 34648141

Haploinsufficiency, Dominant Negative, and Gain-of-Function Mechanisms in Epilepsy: Matching Therapeutic Approach to the Pathophysiology.

Gemma L Carvill1, Tyler Matheny2, Jay Hesselberth2, Scott Demarest3.   

Abstract

This review summarizes the pathogenic mechanisms that underpin the monogenic epilepsies and discusses the potential of novel precision therapeutics to treat these disorders. Pathogenic mechanisms of epilepsy include recessive (null alleles), haploinsufficiency, imprinting, gain-of-function, and dominant negative effects. Understanding which pathogenic mechanism(s) that underlie each genetic epilepsy is pivotal to design precision therapies that are most likely to be beneficial for the patient. Novel therapeutics discussed include gene therapy, gene editing, antisense oligonucleotides, and protein replacement. Discussions are illustrated and reinforced with examples from the literature.
© 2021. The American Society for Experimental NeuroTherapeutics, Inc.

Entities:  

Keywords:  Antisense oligonucleotides; Epilepsy; Gene therapy; Genetics; Precision therapies

Mesh:

Substances:

Year:  2021        PMID: 34648141      PMCID: PMC8608973          DOI: 10.1007/s13311-021-01137-z

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   6.088


  91 in total

1.  Real-world utility of whole exome sequencing with targeted gene analysis for focal epilepsy.

Authors:  Piero Perucca; Ingrid E Scheffer; A Simon Harvey; Paul A James; Sebastian Lunke; Natalie Thorne; Clara Gaff; Brigid M Regan; John A Damiano; Michael S Hildebrand; Samuel F Berkovic; Terence J O'Brien; Patrick Kwan
Journal:  Epilepsy Res       Date:  2017-02-07       Impact factor: 3.045

2.  Role of RNase H in hybrid-arrested translation by antisense oligonucleotides.

Authors:  R Y Walder; J A Walder
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

3.  Base editors for simultaneous introduction of C-to-T and A-to-G mutations.

Authors:  Rina C Sakata; Soh Ishiguro; Hideto Mori; Mamoru Tanaka; Kenji Tatsuno; Hiroki Ueda; Shogo Yamamoto; Motoaki Seki; Nanami Masuyama; Keiji Nishida; Hiroshi Nishimasu; Kazuharu Arakawa; Akihiko Kondo; Osamu Nureki; Masaru Tomita; Hiroyuki Aburatani; Nozomu Yachie
Journal:  Nat Biotechnol       Date:  2020-06-02       Impact factor: 54.908

4.  Case management and critical pathways: friend or foe?

Authors:  L Lynam
Journal:  Neonatal Netw       Date:  1994-12

5.  Rare copy number variants are an important cause of epileptic encephalopathies.

Authors:  Heather C Mefford; Simone C Yendle; Cynthia Hsu; Joseph Cook; Eileen Geraghty; Jacinta M McMahon; Orvar Eeg-Olofsson; Lynette G Sadleir; Deepak Gill; Bruria Ben-Zeev; Tally Lerman-Sagie; Mark Mackay; Jeremy L Freeman; Eva Andermann; James T Pelakanos; Ian Andrews; Geoffrey Wallace; Evan E Eichler; Samuel F Berkovic; Ingrid E Scheffer
Journal:  Ann Neurol       Date:  2011-12       Impact factor: 10.422

Review 6.  Progress in Understanding and Treating SCN2A-Mediated Disorders.

Authors:  Stephan J Sanders; Arthur J Campbell; Jeffrey R Cottrell; Rikke S Moller; Florence F Wagner; Angie L Auldridge; Raphael A Bernier; William A Catterall; Wendy K Chung; James R Empfield; Alfred L George; Joerg F Hipp; Omar Khwaja; Evangelos Kiskinis; Dennis Lal; Dheeraj Malhotra; John J Millichap; Thomas S Otis; Steven Petrou; Geoffrey Pitt; Leah F Schust; Cora M Taylor; Jennifer Tjernagel; John E Spiro; Kevin J Bender
Journal:  Trends Neurosci       Date:  2018-04-23       Impact factor: 13.837

7.  Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy.

Authors:  Deepa Chand; Franziska Mohr; Hugh McMillan; Francis Fonyuy Tukov; Kyle Montgomery; Aaron Kleyn; Rui Sun; Sitra Tauscher-Wisniewski; Petra Kaufmann; Gerd Kullak-Ublick
Journal:  J Hepatol       Date:  2020-11-10       Impact factor: 25.083

Review 8.  Progress toward Gene Therapy for Duchenne Muscular Dystrophy.

Authors:  Joel R Chamberlain; Jeffrey S Chamberlain
Journal:  Mol Ther       Date:  2017-04-15       Impact factor: 12.910

9.  Hybridization-mediated off-target effects of splice-switching antisense oligonucleotides.

Authors:  Juergen Scharner; Wai Kit Ma; Qian Zhang; Kuan-Ting Lin; Frank Rigo; C Frank Bennett; Adrian R Krainer
Journal:  Nucleic Acids Res       Date:  2020-01-24       Impact factor: 16.971

10.  Safety of Direct Intraparenchymal AAVrh.10-Mediated Central Nervous System Gene Therapy for Metachromatic Leukodystrophy.

Authors:  Jonathan B Rosenberg; Alvin Chen; Bishnu P De; Jonathan P Dyke; Douglas J Ballon; Sebastien Monette; Rodolfo J Ricart Arbona; Stephen M Kaminsky; Ronald G Crystal; Dolan Sondhi
Journal:  Hum Gene Ther       Date:  2021-03-30       Impact factor: 4.793

View more
  2 in total

1.  Precision Treatments in Epilepsy.

Authors:  Scott Demarest; Amy Brooks-Kayal
Journal:  Neurotherapeutics       Date:  2021-10-26       Impact factor: 6.088

Review 2.  The Interconnected Mechanisms of Oxidative Stress and Neuroinflammation in Epilepsy.

Authors:  Anna L M Parsons; Eboni M V Bucknor; Enrico Castroflorio; Tânia R Soares; Peter L Oliver; Daniel Rial
Journal:  Antioxidants (Basel)       Date:  2022-01-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.